US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gyre Therapeutics

8.40

-0.4800-5.41%

Post-market: 8.400.00000.00%16:05 EDT

Volume:161.06K

Turnover:1.40M

Market Cap:786.34M

PE:174.72

High:9.39

Open:8.72

Low:8.26

Close:8.88

Loading ...

Overview Company News Filings

BRIEF-Gyre Therapeutics Appoints Ping Zhang To Board Of Directors

Gyre Therapeutics appoints Ping Zhang to board of directors

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

THOMSON REUTERS

Gyre Therapeutics Inc - Ying Luo Resigns as Chairman of Gyre and Gyre Pharmaceuticals

THOMSON REUTERS

Press Release: Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

BRIEF-Gyre Therapeutics Entered Into Open Market Sale Agreement, May Offer & Sell Shares Of Common Stock Of Up To $50 Million From Time To Time

Gyre Therapeutics: Entered Into Open Market Sale Agreement, May Offer & Sell Shares of Common Stock of up to $50 Mln From Time to Time - SEC Filing

THOMSON REUTERS

Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)

Simply Wall St.

Gyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates

Gyre Therapeutics Files $150 Million Mixed Securities Shelf

MT Newswires Live

Gyre Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS

BRIEF-Gyre Therapeutics Reports Third Quarter 2024 And Year-To-Date Financial Results And Provides Business Update

Gyre Therapeutics Q3 Earnings, Revenue Decline

MT Newswires Live

Gyre Therapeutics Q3 2024 GAAP EPS Of $0.01 Vs. $0.05 YoY, With Adjusted Net Income Of $4.39M Vs. $11.19M YoY

Gyre Therapeutics Inc: Qtrly EPS $0.01

THOMSON REUTERS

Gyre Therapeutics Reports Third Quarter 2024 and Year-to-Date Financial Results and Provides Business Update

THOMSON REUTERS

Gyre Therapeutics Q3 Net Income USD 2.9 Million

THOMSON REUTERS

Corrected-Gyre Therapeutics Q3 Revenue USD 25.5 Million (Corrects Amount)

THOMSON REUTERS

Gyre Therapeutics Q3 Revenue USD 25.3 Million

THOMSON REUTERS

Press Release: Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":8.4,"timestamp":1745265600000,"preClose":8.88,"halted":0,"volume":161062,"hourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.4,"latestTime":"16:05 EDT","volume":946,"amount":7946.400000000001,"timestamp":1745265911064},"delay":0,"floatShares":16648400,"shares":93612442,"eps":0.048077,"marketStatus":"Post-Mkt","change":-0.48,"latestTime":"04-21 18:27:06 EDT","open":8.72,"high":9.385,"low":8.26,"amount":1395694.182309,"amplitude":0.126689,"askPrice":9.5,"askSize":250,"bidPrice":7.67,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.048077,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":8.88,"preHourTrading":{"tag":"盘前","latestPrice":8.61,"preClose":8.88,"latestTime":"06:55 EDT","volume":302,"amount":2563.409824,"timestamp":1745232913694},"postHourTrading":{"tag":"盘后","latestPrice":8.4,"preClose":8.4,"latestTime":"16:05 EDT","volume":946,"amount":7946.400000000001,"timestamp":1745265911064},"volumeRatio":1.61533,"impliedVol":0.2912,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GYRE\",,,,,undefined,":{"symbol":"GYRE","floatShares":16648400,"roa":"8.38%","roe":"20.24%","lyrEps":0.142017,"volumeRatio":1.61533,"shares":93612442,"dividePrice":0,"high":9.385,"amplitude":0.126689,"preClose":8.88,"low":8.26,"week52Low":6.11,"pbRate":"12.42","psRate":"7.44","week52High":19,"institutionHeld":0.0314,"latestPrice":8.4,"committee":-0.428571,"eps":0.048077,"divideRate":0,"volume":161062,"delay":0,"ttmEps":0.048077,"open":8.72,"prevYearClose":12.1,"prevWeekClose":8.88,"prevMonthClose":7.72,"prevQuarterClose":7.72,"fiveDayClose":7.52,"twentyDayClose":9.71,"sixtyDayClose":10.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501411233","title":"BRIEF-Gyre Therapeutics Appoints Ping Zhang To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501411233","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501411233?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:16","pubTimestamp":1736165800,"startTime":"0","endTime":"0","summary":"BRIEF-Gyre Therapeutics Appoints Ping Zhang To Board Of DirectorsJan 6 (Reuters) - Asian Star Co 8946.T:GYRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF PING ZHANG TO BOARD OF DIRECTORSGYRE THERAPEUTICS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUABV0MZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2501332832","title":"Gyre Therapeutics appoints Ping Zhang to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501332832","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501332832?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:12","pubTimestamp":1736165579,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) announced the appointment of Ping Zhang to its Board of Directors as the lead independent director of the Board and a memb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-appoints-ping-zhang-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gyre-therapeutics-appoints-ping-zhang-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2501384462","title":"Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501384462","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501384462?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUABV0MZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2501238443","title":"Gyre Therapeutics Inc - Ying Luo Resigns as Chairman of Gyre and Gyre Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2501238443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501238443?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUABV0MZQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2501384802","title":"Press Release: Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2501384802","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501384802?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:00","pubTimestamp":1736164800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 06, 2025  -- Gyre Therapeutics  , a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of Ping Zhang to its Board of Directors  as the lead independent director of the Board and a member of the Nominating and Corporate Governance Committee of the Board. In addition, Ying Luo, Ph.D. resigned as Chairman and a member of the Board of Directors of Gyre and Gyre Pharmaceuticals, Gyre's majority indirectly owned subsidiary in the People's Republic of China , to focus on other responsibilities at GNI Group Ltd. Songjiang Ma has been appointed Chairman of the Board of Directors of Gyre Pharmaceuticals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","R","GYRE","BK4022"],"gpt_icon":0},{"id":"2486721389","title":"BRIEF-Gyre Therapeutics Entered Into Open Market Sale Agreement, May Offer & Sell Shares Of Common Stock Of Up To $50 Million From Time To Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2486721389","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486721389?lang=en_us&edition=fundamental","pubTime":"2024-11-28 07:21","pubTimestamp":1732749674,"startTime":"0","endTime":"0","summary":"Nov 27 (Reuters) - Gyre Therapeutics Inc   :   * GYRE THERAPEUTICS: ENTERED INTO OPEN MARKET SALE AGREEMENT, MAY OFFER & SELL SHARES OF COMMON STOCK OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2486800864","title":"Gyre Therapeutics: Entered Into Open Market Sale Agreement, May Offer & Sell Shares of Common Stock of up to $50 Mln From Time to Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2486800864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486800864?lang=en_us&edition=fundamental","pubTime":"2024-11-28 05:23","pubTimestamp":1732742620,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY1F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2483322593","title":"Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322593","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483322593?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:27","pubTimestamp":1731670032,"startTime":"0","endTime":"0","summary":"NasdaqCM:GYRE Earnings and Revenue History November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Gyre Therapeutics shares are down 8.1% from a week ago.Don't forget that there may still be risks. For instance, we've identified   4 warning signs for Gyre Therapeutics   you should be aware of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gyre-therapeutics-third-quarter-2024-112712072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GYRE"],"gpt_icon":0},{"id":"2483394244","title":"Gyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483394244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483394244?lang=en_us&edition=fundamental","pubTime":"2024-11-15 12:37","pubTimestamp":1731645438,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Inc ( ($GYRE) ) has released its Q3 earnings. Here is a breakdown of the information Gyre Therapeutics Inc presented to its inves...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-q3-2024-financial-results-and-strategic-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gyre-therapeutics-reports-q3-2024-financial-results-and-strategic-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2483594623","title":"Gyre Therapeutics Files $150 Million Mixed Securities Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2483594623","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483594623?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:37","pubTimestamp":1731623830,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics  filed a shelf registration statement with the US Securities and Exchange Commission Thursday covering the potential sale of up to $150 million of its securities from time to time in one or more offerings.The statement covers common and preferred shares, debt securities, warrants, and units.The company said it will use the net proceeds generated from any securities sale for development, manufacturing, and scale-up, as well as for working capital and general corporate purposes, among other things.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2483723358","title":"Gyre Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483723358","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483723358?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:40","pubTimestamp":1731620451,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2483009050","title":"BRIEF-Gyre Therapeutics Reports Third Quarter 2024 And Year-To-Date Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483009050","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483009050?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:28","pubTimestamp":1731500883,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Gyre Therapeutics Inc   :   * GYRE THERAPEUTICS REPORTS THIRD QUARTER 2024 AND YEAR-TO-DATE FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE   * GYRE THERAPEUTICS INC: QTRLY EPS $0.01Source text:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2483182003","title":"Gyre Therapeutics Q3 Earnings, Revenue Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483182003","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483182003?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:42","pubTimestamp":1731498142,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics (GYRE) reported Q3 earnings Wednesday of $0.01 per diluted share, down from $0.05 a year earlier.Revenue for the quarter ended Sept. 30 was $25.5 million, down from $32 million a year earlier.Analysts' estimates were not readily available for comparison.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GYRE"],"gpt_icon":0},{"id":"2483772270","title":"Gyre Therapeutics Q3 2024 GAAP EPS Of $0.01 Vs. $0.05 YoY, With Adjusted Net Income Of $4.39M Vs. $11.19M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483772270","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483772270?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:07","pubTimestamp":1731496059,"startTime":"0","endTime":"0","summary":"As of September 30, 2024, Gyre had cash and cash equivalents of $15.9 million. Based on current plans, Gyre anticipates that its cash resources as of September 30, 2024 will enable it to fund operations through at least","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41933596/gyre-therapeutics-q3-2024-gaap-eps-of-0-01-vs-0-05-yoy-with-adjusted-net-income-of-4-39m-vs-11-19","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gyre Therapeutics Q3 2024 GAAP EPS Of $0.01 Vs. $0.05 YoY, With Adjusted Net Income Of $4.39M Vs. $11.19M YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE"],"gpt_icon":0},{"id":"2483907752","title":"Gyre Therapeutics Inc: Qtrly EPS $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2483907752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483907752?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1Z9907:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2483775780","title":"Gyre Therapeutics Reports Third Quarter 2024 and Year-to-Date Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483775780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483775780?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA1Z9907:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2483077688","title":"Gyre Therapeutics Q3 Net Income USD 2.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077688?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX9B2A4B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GYRE"],"gpt_icon":0},{"id":"2483009188","title":"Corrected-Gyre Therapeutics Q3 Revenue USD 25.5 Million (Corrects Amount)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483009188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483009188?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX9B2A4B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2483077656","title":"Gyre Therapeutics Q3 Revenue USD 25.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077656?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX9B2A4B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GYRE","BK4139"],"gpt_icon":0},{"id":"2483077955","title":"Press Release: Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483077955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483077955?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update. Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025. On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025. \"Our team has made great progress over the last several months and recently achieved a significant milestone with the final patient completing 52 weeks of study in our pivotal Phase 3 trial for F351 in CHB-associated liver fibrosis. We are encouraged by F351's potential as a novel treatment for this fibrotic disease and are excited to share topline results in the first quarter 2025,\" said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. \"With several upcoming milestones in 2025, including the commercial launch of two new products in the PRC as well as the anticipated initiation of a U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis, we remain con","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GYRE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-17","symbol":"GYRE","fiscalQuarterEnding":"2024/12","expectedEps":0.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"post","actualEps":0.01},{"date":"2025-02-18","symbol":"GYRE","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739869200000,"name":null,"time":"Pre-Market","dateTimestamp":1739854800000,"actualEps":null},{"market":"US","date":"2024-11-13","symbol":"GYRE","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":0.02},{"market":"US","date":"2024-08-13","symbol":"GYRE","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":0.01},{"market":"US","date":"2024-05-09","symbol":"GYRE","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GYRE","date":"2025-04-17","current":61.504575,"percent":0.955102,"low":-11548.718266,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"high":95.122945,"avg":-1400.455177,"sd":3328.303917,"marketCap":743282789},"quantilePoints":[{"date":"2024-04-05","current":-15.607876,"twenty":-15.830217,"median":-15.617068,"eighty":-15.398378,"marketCap":1450486717},{"date":"2024-04-12","current":-31.76291,"twenty":-32.589325,"median":-21.429161,"eighty":-15.61523,"marketCap":1405212396},{"date":"2024-04-19","current":-29.754799,"twenty":-32.477335,"median":-30.585076,"eighty":-15.742078,"marketCap":1316372220},{"date":"2024-04-26","current":-31.531205,"twenty":-31.948274,"median":-30.797472,"eighty":-16.000876,"marketCap":1394961607},{"date":"2024-05-03","current":-27.239192,"twenty":-31.948274,"median":-30.778163,"eighty":-24.631989,"marketCap":1205080075},{"date":"2024-05-10","current":-14.851474,"twenty":-31.774495,"median":-30.223912,"eighty":-24.631989,"marketCap":1301657414},{"date":"2024-05-17","current":-14.909982,"twenty":-31.744918,"median":-29.754799,"eighty":-15.561911,"marketCap":1306785414},{"date":"2024-05-24","current":-12.302842,"twenty":-31.573048,"median":-28.630129,"eighty":-14.89828,"marketCap":1078282562},{"date":"2024-05-31","current":-8605.737804,"twenty":-32.075712,"median":-29.501562,"eighty":-15.108912,"marketCap":890160307},{"date":"2024-06-07","current":-8895.075775,"twenty":-32.90985,"median":-30.136978,"eighty":-15.311743,"marketCap":920088848},{"date":"2024-06-14","current":-9126.546144,"twenty":-8519.763095,"median":-30.585076,"eighty":-15.366351,"marketCap":944031680},{"date":"2024-06-21","current":-8961.210165,"twenty":-8885.155616,"median":-30.816781,"eighty":-15.424018,"marketCap":926929657},{"date":"2024-06-28","current":-8175.864257,"twenty":-8865.315298,"median":-30.894016,"eighty":-15.515947,"marketCap":845695047},{"date":"2024-07-05","current":-9688.68848,"twenty":-8961.210165,"median":-31.531205,"eighty":-15.611553,"marketCap":1002178559},{"date":"2024-07-12","current":-10424.433593,"twenty":-9151.346542,"median":-31.791873,"eighty":-15.679573,"marketCap":1078282562},{"date":"2024-07-15","current":-11094.044316,"twenty":-9210.867496,"median":-31.820836,"eighty":-15.710825,"marketCap":1147545756},{"date":"2024-08-02","current":-11548.718266,"twenty":-9298.495565,"median":-32.139431,"eighty":-15.742078,"marketCap":1194576320},{"date":"2024-08-09","current":-8374.267436,"twenty":-9189.373818,"median":-32.728348,"eighty":-16.000876,"marketCap":866217475},{"date":"2024-08-16","current":-10.635127,"twenty":-9134.812943,"median":-32.641458,"eighty":-15.61523,"marketCap":914301855},{"date":"2024-08-23","current":-11.421808,"twenty":-9126.546144,"median":-31.820836,"eighty":-15.175222,"marketCap":981932798},{"date":"2024-08-30","current":-13.672312,"twenty":-9020.73112,"median":-31.635813,"eighty":-14.375603,"marketCap":1175408659},{"date":"2024-09-06","current":-11.770337,"twenty":-8974.437045,"median":-30.942288,"eighty":-13.816505,"marketCap":1011895874},{"date":"2024-09-13","current":-14.920484,"twenty":-8961.210165,"median":-30.778163,"eighty":-13.696211,"marketCap":1282714046},{"date":"2024-09-20","current":-15.572509,"twenty":-8941.369845,"median":-30.223912,"eighty":-13.816505,"marketCap":1338768556},{"date":"2024-09-27","current":-13.909847,"twenty":-8923.182886,"median":-29.754799,"eighty":-13.90034,"marketCap":1195829555},{"date":"2024-10-04","current":-13.312158,"twenty":-8919.876167,"median":-28.630129,"eighty":-13.654308,"marketCap":1144446254},{"date":"2024-10-11","current":-12.327984,"twenty":-8904.995932,"median":-26.800559,"eighty":-13.325198,"marketCap":1059836795},{"date":"2024-10-18","current":-15.235629,"twenty":-8865.315298,"median":-15.915547,"eighty":-13.300875,"marketCap":1309807059},{"date":"2024-10-25","current":-15.300832,"twenty":-8830.594739,"median":-15.607876,"eighty":-13.325198,"marketCap":1315412510},{"date":"2024-10-31","current":-15.985457,"twenty":-8804.140979,"median":-15.617068,"eighty":-13.405529,"marketCap":1374269746},{"date":"2024-11-08","current":-16.365804,"twenty":-8779.340581,"median":-15.748988,"eighty":-13.558712,"marketCap":1406968211},{"date":"2024-11-15","current":-13.372591,"twenty":-8709.89947,"median":-15.77333,"eighty":-13.558712,"marketCap":1187780244},{"date":"2024-11-22","current":-11.353175,"twenty":-8602.431085,"median":-15.627389,"eighty":-13.295234,"marketCap":1008411696},{"date":"2024-11-29","current":-12.087508,"twenty":-8556.137012,"median":-15.590193,"eighty":-13.126615,"marketCap":1073636622},{"date":"2024-12-06","current":-10.111572,"twenty":-8387.494312,"median":-15.378053,"eighty":-12.781935,"marketCap":898130076},{"date":"2024-12-13","current":-9.449706,"twenty":-8374.267436,"median":-15.329691,"eighty":-12.475931,"marketCap":839341820},{"date":"2024-12-20","current":-10.299987,"twenty":-8344.506959,"median":-15.279098,"eighty":-12.329976,"marketCap":914865419},{"date":"2024-12-27","current":-12.686569,"twenty":-8225.465052,"median":-15.246496,"eighty":-12.302842,"marketCap":1126846431},{"date":"2025-01-03","current":-11.594732,"twenty":-8192.397854,"median":-15.235629,"eighty":-12.152426,"marketCap":1029867264},{"date":"2025-01-10","current":-9.29511,"twenty":-8179.170976,"median":-15.105225,"eighty":-11.98162,"marketCap":825610256},{"date":"2025-01-17","current":-10.435259,"twenty":-3290.168076,"median":-14.953086,"eighty":-11.68749,"marketCap":926880537},{"date":"2025-01-24","current":-10.242013,"twenty":-32.95233,"median":-14.893499,"eighty":-11.536758,"marketCap":909716083},{"date":"2025-01-31","current":-11.111618,"twenty":-32.786274,"median":-14.681409,"eighty":-11.380628,"marketCap":986956128},{"date":"2025-02-07","current":-12.319402,"twenty":-32.658836,"median":-14.539395,"eighty":-11.347378,"marketCap":1094233968},{"date":"2025-02-14","current":-11.382162,"twenty":-32.515952,"median":-14.451664,"eighty":-11.279742,"marketCap":1010986364},{"date":"2025-02-21","current":-12.135819,"twenty":-32.330588,"median":-14.072853,"eighty":-11.345445,"marketCap":1077927736},{"date":"2025-02-28","current":-10.90871,"twenty":-31.809251,"median":-13.976035,"eighty":-11.179254,"marketCap":968933450},{"date":"2025-03-07","current":-10.338636,"twenty":-31.758412,"median":-13.909847,"eighty":-11.12128,"marketCap":918298310},{"date":"2025-03-14","current":-11.556083,"twenty":-31.698577,"median":-13.789262,"eighty":-11.11355,"marketCap":1026434373},{"date":"2025-03-21","current":79.165838,"twenty":-31.423076,"median":-13.627303,"eighty":-11.045914,"marketCap":956719157},{"date":"2025-03-28","current":70.412668,"twenty":-30.971251,"median":-13.353241,"eighty":-10.90871,"marketCap":850937097},{"date":"2025-04-04","current":52.673943,"twenty":-30.878569,"median":-13.283951,"eighty":-10.748316,"marketCap":636564605},{"date":"2025-04-11","current":56.469566,"twenty":-30.809057,"median":-13.129602,"eighty":-10.622099,"marketCap":682434702},{"date":"2025-04-17","current":61.504575,"twenty":-30.778163,"median":-12.849861,"eighty":-10.560868,"marketCap":743282789}],"updateTime":1745232576999}}}